GENUS SARABIA: Open Payments
NPI 1720647944 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$400 in 19 payments from 7 companies in 2025. Trend: 2023 $1,193 · 2024 $1,356 · 2025 $400
Food & beverage: $400
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 7 | $141 |
| Merck Sharp & Dohme LLC | 2 | $61 |
| ABBVIE INC. | 3 | $56 |
| Shionogi Inc | 2 | $42 |
| Melinta Therapeutics, LLC | 2 | $42 |
| Gilead Sciences, Inc. | 2 | $42 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
Products named: CABENUVA, Fetroja, AVYCAZ, ZERBAXA, PIFELTRO, Kimyrsa, Yeztugo, DALVANCE.
Industry payments across NV — which companies pay providers there.
